Literature DB >> 11064491

When "enough" is not enough: new perspectives on optimal methadone maintenance dose.

S B Leavitt1, M Shinderman, S Maxwell, C B Eap, P Paris.   

Abstract

Some methadone maintenance treatment (MMT) programs prescribe inadequate daily methadone doses. Patients complain of withdrawal symptoms and continue illicit opioid use, yet practitioners are reluctant to increase doses above certain arbitrary thresholds. Serum methadone levels (SMLs) may guide practitioners dosing decisions, especially for those patients who have low SMLs despite higher methadone doses. Such variation is due in part to the complexities of methadone metabolism. The medication itself is a racemic (50:50) mixture of 2 enantiomers: an active "R" form and an essentially inactive "S" form. Methadone is metabolized primarily in the liver, by up to five cytochrome P450 isoforms, and individual differences in enzyme activity help explain wide ranges of active R-enantiomer concentrations in patients given identical doses of racemic methadone. Most clinical research studies have used methadone doses of less than 100 mg/day [d] and have not reported corresponding SMLs. New research suggests that doses ranging from 120 mg/d to more than 700 mg/d, with correspondingly higher SMLs, may be optimal for many patients. Each patient presents a unique clinical challenge, and there is no way of prescribing a single best methadone dose to achieve a specific blood level as a "gold standard" for all patients. Clinical signs and patient-reported symptoms of abstinence syndrome, and continuing illicit opioid use, are effective indicators of dose inadequacy. There does not appear to be a maximum daily dose limit when determining what is adequately "enough" methadone in MMT.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11064491

Source DB:  PubMed          Journal:  Mt Sinai J Med        ISSN: 0027-2507


  21 in total

1.  Interaction between Methadone and Ciprofloxacin.

Authors:  Leslie Samoy; Karen F Shalansky
Journal:  Can J Hosp Pharm       Date:  2010-09

Review 2.  Pharmacological Management of Opioid Use Disorder in Pregnant Women.

Authors:  Christine M Wilder; Theresa Winhusen
Journal:  CNS Drugs       Date:  2015-08       Impact factor: 5.749

Review 3.  Interindividual variability of the clinical pharmacokinetics of methadone: implications for the treatment of opioid dependence.

Authors:  Chin B Eap; Thierry Buclin; Pierre Baumann
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

4.  Treatment of opioid use disorder in an innovative community-based setting after multiple treatment attempts in a woman with untreated HIV.

Authors:  Pauline Voon; Ronald Joe; Christopher Fairgrieve; Keith Ahamad
Journal:  BMJ Case Rep       Date:  2016-07-11

5.  Estimated infant exposure to enantiomer-specific methadone levels in breastmilk.

Authors:  Debra L Bogen; James M Perel; Joseph C Helsel; Barbara H Hanusa; Matthew Thompson; Katherine L Wisner
Journal:  Breastfeed Med       Date:  2011-02-24       Impact factor: 1.817

6.  A qualitative study exploring the reason for low dosage of methadone prescribed in the MMT clinics in China.

Authors:  Chunqing Lin; Roger Detels
Journal:  Drug Alcohol Depend       Date:  2011-02-09       Impact factor: 4.492

7.  Medication-assisted treatment for opioid addiction: methadone and buprenorphine.

Authors:  Andrew J Saxon; Yih-Ing Hser; George Woody; Walter Ling
Journal:  J Food Drug Anal       Date:  2013-12       Impact factor: 6.079

8.  Human resource development and capacity-building during China's rapid scale-up of methadone maintenance treatment services.

Authors:  Jianhua Li; Changhe Wang; Jennifer M McGoogan; Keming Rou; Marc Bulterys; Zunyou Wu
Journal:  Bull World Health Organ       Date:  2013-02-01       Impact factor: 9.408

Review 9.  Methadone: a new old drug with promises and pitfalls.

Authors:  Jodie A Trafton; Abhinav Ramani
Journal:  Curr Pain Headache Rep       Date:  2009-02

10.  A meta-analysis of retention in methadone maintenance by dose and dosing strategy.

Authors:  Yan-Ping Bao; Zhi-Min Liu; David H Epstein; Cun Du; Jie Shi; Lin Lu
Journal:  Am J Drug Alcohol Abuse       Date:  2009       Impact factor: 3.829

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.